Literature DB >> 24389948

Local delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs.

Tegan L Cheng1, Ciara M Murphy, Laurence C Cantrill, Kathy Mikulec, Clare Carpenter, Aaron Schindeler, David G Little.   

Abstract

PURPOSE: Legg-Calve-Perthes disease is a paediatric condition encompassing idiopathic osteonecrosis of the femoral head (ONFH). Preventing collapse and the need for subsequent joint replacement remains the major goal of clinical management. This exploratory study utilises a porcine model of surgically induced ONFH.
METHODS: rhBMP-2 with and without zoledronic acid (ZA) was delivered by intra-osseous injection in the phase-transitioning sucrose acetate isobutyrate (SAIB) in an attempt to prevent femoral head collapse. Epiphyseal quotient (EQ) at eight weeks post-surgery was the primary outcome measure. Heterotopic ossification in the joint capsule and bisphosphonate retention in the femoral head were key secondary outcomes.
RESULTS: Femoral heads with ONFH and no treatment all collapsed (3/3, EQ < 0.4, P < 0.05 compared to no ONFH). Local delivery of rhBMP-2/SAIB into the femoral head prevented collapse by EQ measurement one of four samples; however, this specimen still showed evidence of significant collapse. In contrast, the combination of local rhBMP-2 and local ZA prevented collapse in two of four samples. Confocal fluorescence microscopy showed locally dosed bisphosphonate entered and was retained in the femoral head. This group also showed strong Calcein signal, indicating new bone formation. Treatment with rhBMP-2 was associated with a limited amount of heterotrophic ossification in the joint capsules in some specimens.
CONCLUSIONS: Operators reported SAIB to be an efficient way to deliver rhBMP-2 to the femoral head. These data suggest that rhBMP-2 is ineffective for preventing femoral head collapse without the addition of bisphosphonate. Further research will be required to validate the clinical efficacy of a combined local rhBMP-2/bisphosphonate approach.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24389948      PMCID: PMC4071497          DOI: 10.1007/s00264-013-2255-0

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  30 in total

1.  Collagen-chondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for bone repair.

Authors:  Dilek Sendil Keskin; Aysen Tezcaner; Petek Korkusuz; Feza Korkusuz; Vasif Hasirci
Journal:  Biomaterials       Date:  2005-06       Impact factor: 12.479

2.  Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.

Authors:  ThiThuyAn Nguyen; Margaret R Zacharin
Journal:  J Pediatr Endocrinol Metab       Date:  2006-02       Impact factor: 1.634

3.  The natural history of Legg-Calvé-Perthes disease.

Authors:  S D Stulberg; D R Cooperman; R Wallensten
Journal:  J Bone Joint Surg Am       Date:  1981-09       Impact factor: 5.284

4.  Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.

Authors:  David G Little; Michelle McDonald; Ian T Sharpe; Rachel Peat; Paul Williams; Tony McEvoy
Journal:  J Orthop Res       Date:  2005-02-25       Impact factor: 3.494

5.  Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts.

Authors:  H Kaneko; T Arakawa; H Mano; T Kaneda; A Ogasawara; M Nakagawa; Y Toyama; Y Yabe; M Kumegawa; Y Hakeda
Journal:  Bone       Date:  2000-10       Impact factor: 4.398

6.  Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.

Authors:  David G Little; Michelle McDonald; Rick Bransford; Craig B Godfrey; Negin Amanat
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

7.  Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.

Authors:  Harry K W Kim; Timothy S Randall; Haikuo Bian; Joe Jenkins; Amanda Garces; Frieder Bauss
Journal:  J Bone Joint Surg Am       Date:  2005-03       Impact factor: 5.284

8.  Usefulness of epiphyseal quotient measurement on magnetic resonance images for outcome prediction in patients with early-stage Legg-Calve-Perthes disease.

Authors:  Yuichi Tsuchida; Wook-Cheol Kim; Kenji A Takahashi; Motoyuki Horii; Yasuo Mikami; Mikihiro Fujioka; Torao Kusakabe; Kyung Chang; Motoo Hosokawa; Toshikazu Kubo
Journal:  J Pediatr Orthop B       Date:  2005-01       Impact factor: 1.041

9.  Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model.

Authors:  Harry K W Kim; Phi-Huynh Su
Journal:  J Bone Joint Surg Am       Date:  2002-08       Impact factor: 5.284

10.  Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.

Authors:  David G Little; Rachel A Peat; Anthony Mcevoy; Paul R Williams; Elisabeth J Smith; Paul A Baldock
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

View more
  7 in total

1.  Endothelial nitric oxide synthase gene polymorphism is associated with Legg-Calvé-Perthes disease.

Authors:  Yulong Zhao; Shijie Liao; Rongbin Lu; Hao Dang; Jinmin Zhao; Xiaofei Ding
Journal:  Exp Ther Med       Date:  2016-02-26       Impact factor: 2.447

2.  Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use?

Authors:  Aurélien Courvoisier; Frederic Sailhan; Olivier Laffenêtre; Laurent Obert
Journal:  Int Orthop       Date:  2014-09-30       Impact factor: 3.075

3.  A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head.

Authors:  Yutaka Kuroda; Ryuta Asada; Kazutaka So; Atsushi Yonezawa; Manabu Nankaku; Kumi Mukai; Toshiko Ito-Ihara; Harue Tada; Michio Yamamoto; Toshinori Murayama; Satoshi Morita; Yasuhiko Tabata; Masayuki Yokode; Akira Shimizu; Shuichi Matsuda; Haruhiko Akiyama
Journal:  Int Orthop       Date:  2015-12-29       Impact factor: 3.075

Review 4.  Available Findings Fail to Provide Strong Evidence of the Role of Bone Morphogenic Protein-2 in Femoral Head Osteonecrosis.

Authors:  Ali Parsa; Hamed Vahedi; Karan Goswami; Arash Aalirezaie
Journal:  Arch Bone Jt Surg       Date:  2020-01

5.  Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials.

Authors:  Donghai Li; Zhouyuan Yang; Zhun Wei; Pengde Kang
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

6.  Induction of periosteal bone formation by intraosseous BMP-2 injection in a mouse model of osteogenesis imperfecta.

Authors:  T L Cheng; L C Cantrill; A Schindeler; D G Little
Journal:  J Child Orthop       Date:  2019-10-01       Impact factor: 1.548

Review 7.  Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy.

Authors:  Arbi Aghali
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.